Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) Return on Invested Capital (2017 - 2025)

Voyager Therapeutics' Return on Invested Capital history spans 5 years, with the latest figure at 0.12% for Q4 2025.

  • For Q4 2025, Return on Invested Capital rose 15.0% year-over-year to 0.12%; the TTM value through Dec 2025 reached 0.12%, up 15.0%, while the annual FY2025 figure was 0.1%, 21.0% up from the prior year.
  • Return on Invested Capital for Q4 2025 was 0.12% at Voyager Therapeutics, up from 0.61% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.67% in Q1 2023 and bottomed at 0.61% in Q3 2025.
  • The 3-year median for Return on Invested Capital is 0.26% (2024), against an average of 0.12%.
  • The largest annual shift saw Return on Invested Capital tumbled -118bps in 2024 before it increased 15bps in 2025.
  • A 3-year view of Return on Invested Capital shows it stood at 0.13% in 2023, then tumbled by -298bps to 0.27% in 2024, then skyrocketed by 55bps to 0.12% in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Return on Invested Capital are 0.12% (Q4 2025), 0.61% (Q3 2025), and 0.48% (Q2 2025).